EU Simoa® Success Seminar: Lisbon
dateOctober 3-4, 2023
October 3rd – 4th, 2023 | Hyatt Regency Lisbon, R. da Junqueira 65, 1300-343 Lisbon, Portugal
Optimize your Simoa® experience!
Connect with accomplished users of our ultrasensitive Simoa® technology and learn about assay development, Simoa® best practices, and more.
Join us for technical presentations from Quanterix and Simoa® users, workshops, Simoa® users poster session, and networking opportunities. Agenda is listed below.
|Day 1: Tuesday, 3rd October | Moderator: Danilo La Terra, Senior Field Application Scientist, Quanterix|
|14.00-14.10||Opening remarks Milena Milutinovic PhD, Senior Manager Field Applications, Quanterix|
|14.10-14.40||Scaling up Simoa®: Preparing for large kit projects Lindsey Marsh PhD, Senior Field Application Scientist, Quanterix|
|14.40-15.10||High sensitivity phenotyping of extracellular vesicles Alessandro Gori PhD, National Research Council of Italy (SCITEC-CNR)|
|15.10-15.40||A CROs guide to homebrewing success: Awkward antibodies & sensitive solutions Daniel Creed, Senior Scientist, Resolian, UK|
|16.10-16.40||Simoa data analysis Victor Liman, Manager Technical Applications, Quanterix|
|16.40-17.10||Quanterix service overview and qualification tips & tricks Quanterix Service Team|
|Day 2: Wednesday, 4th October | Moderator: Ilaria Mancini, Field Application Scientist, Quanterix|
|9.00-9.30||LucentAD and Quanterix’s diagnostic strategy Zachary Fernandes, Director, Global Channel Strategy, Quanterix|
|9.30-10.00||The new normal – Detecting Alzheimer’s disease pathology through blood tests Hanna Huber PhD, Neurochemistry department at the University of Gothenburg, Sweden|
|10.00-10.30||NfL reflects neuron damage in in vitro models of acute brain injury Massimiliano De Paola PhD, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy|
|11.15-11.30||Simoa® in oncology: Now and in future Byron Shen PhD, Director, Oncology Business Development, Quanterix|
|11.30-11.45||Translational Simoa® sensitivity blood-based biomarkers for neurological drug development and clinical trial support Mark Roskey PhD, Chief Science and Collaboration Officer, Quanterix|
|11.45-12.30||Simoa® Best practices, Open Discussion:Group A) HD-X, B) SR-X, C) SP-X|
|12.30-12.45||Closing remarks Milena Milutinovic PhD, Senior Manager Field Applications, Quanterix|
Share this page